Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 7, 2016, Pages 1050-1058

  Chan, June M ^a   Darke, Amy K ^b   Penney, Kathryn L ^c,d   Tangen, Catherine M ^b   Goodman, Phyllis J ^b   Lee, Gwo Shu Mary ^d   Sun, Tong ^d   Peisch, Sam ^d   Tinianow, Alex M ^c   Rae, James M ^e   Klein, Eric A ^f   Thompson, Ian M ^g   Kantoff, Philip W ^d,h   Mucci, Lorelei A ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g University of Texas Health Science Center at San Antonio   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CATALASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 6; PLACEBO; PROTEIN; SEC14L2 PROTEIN; SELENIUM; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE 2; TTPA PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; BLOOD; CANCER GRADING; GENETIC VARIATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHARMACOGENETIC VARIANT; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

AGED; BIOLOGICAL TRANSPORT; BIOMARKERS, TUMOR; COHORT STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; VITAMIN E;

EID: 84977112000     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0104     Document Type: Article

References (62)

1. Clark LC, Dalkin B, Krongrad A, Combs GF, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81: 730-4
2. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Harman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6
3. Clark LC, Combs GFJr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63
4. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23
5. Nomura AM, Lee J, Stemmermann GN, Combs GF. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7
6. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8
7. van Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003;12:866-71
8. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, et al. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005;97:396-9
9. Yoshizawa K,Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24
10. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51
11. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, et al. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res 2014;7: 886-95
12. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014;106: djt456
13. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, et al. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 2013;73:1786-95
14. Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, et al. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate 2013;73:700-5
15. Platz EA. Is prostate cancer prevention with selenium all in the genes? Cancer Prev Res 2010;3:576-8
16. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res 2010;3:604-10
17. Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, et al. Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk. Cancer Res 2009;69: 1429-38
18. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010;19:2958-68
19. Geybels MS, van Brandt PA, Schouten LJ, van Schooten FJ, van Breda SG, Rayman MP, et al. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 2014;106:dju003
20. Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, et al. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2013;73:734-42
21. Grundmark B, Zethelius B, Garmo H, Holmberg L. Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow-up. BMC Cancer 2011;11:431
22. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, Rayman MP. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008;68:10171-7
23. Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MI, Combs GFJr, et al. Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. Prostate 2012;72:1006-12
24. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11: 1513-30
25. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:23-9
26. van Gils CH, Bostick RM, Stern MC, Taylor JA. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev 2002;11:1279-84
27. Zhang J, Dhakal IB, Greene G, Lang NP, Kadlubar FF. Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 2010;75:779-85
28. Park JY, Huang Y, Sellers TA. Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk.Methods Mol Biol 2009;471:361-85
29. Kim YJ, Baek SH, Bogner PN, Clement IP, Rustum YM, Fakih MG, et al. Targeting the Nrf2-Prx1 pathwaywith selenium to enhance the efficacy and selectivity of cancer therapy. J Cancer Molecules 2007;3:37-43
30. Raatikainen S, Aaaltomaa S, Karja V, Soini Y. Increased peroxiredoxin 6 expression predicts biochemical recurrence in prostate cancer patients after radical prostatectomy. Anticancer Res 2015;35:6465-70
31. Whitaker HC, Patel D, Howat WJ, Warren AY, Kay JD, Sangan T, et al. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br J Cancer 2013; 109:983-93
32. Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells invitro. J Proteome Res 2012;11:2452-66
33. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T, et al. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radic Biol Med 2011;51:78-87
34. Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, et al. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 2011;71:755-65
35. Schultz MA, Abdel-Mageed AB, Mondal D. The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells. Cancers 2010;2:1354-78
36. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 2009;7:1543-52
37. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007;67:9294-303
38. Shen C, Nathan C. Nonredundant antioxidant defense by multiple twocysteine peroxiredoxins in human prostate cancer cells. Mol Med 2002; 8:95-102
39. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006;16:420-6
40. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, et al. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 2007;16:1581-6
41. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11
42. Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, et al. Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer. J Nutr 2014;144:729-33
43. Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, et al. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 2015;75:60-9
44. Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 2012;501:89-103
45. Sun GG, Wang YD, Lu YF, Hu WN. Different association of manganese superoxide dismutase gene polymorphisms with risk of prostate, esophageal, and lung cancers: evidence from a meta-analysis of 20,025 subjects. Asian Pac J Cancer Prev 2013;14:1937-43
46. Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol 2010;136:975-9
47. Wang S, Wang F, Shi X, Dai J, Peng Y, Guo X, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk-A meta-analysis. Eur J Cancer 2009;45:2874-81
48. Liwei L, Chunyu L, Ruifa H. Association between manganese superoxide dismutase gene polymorphismand risk of prostate cancer: ameta-analysis. Urology 2009;74:884-8
49. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-504
50. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, et al. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011;107: 126-34
51. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, et al. Plasma selenium, manganese superoxide dismutase, and intermediate-or highrisk prostate cancer. J Clin Oncol 2009;27:3577-83
52. Meplan C, Rohrmann S, Steinbrecher A, Schomburg L, Jansen E, Linseisen J, et al. Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer. PLoS One 2012;7: e48709
53. Battisti V, Maders LD, Bagatini MD, Reetz LG, Chiesa J, Battisti IE, et al. Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomed Pharmacother 2011;65:516-24
54. Koyama K, Takahara K, Inamoto T, Ibuki N, Minami K, Uehara H, et al. E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells. Prostate Int 2015;3:16-21
55. Yao B, Zhao J, Li Y, Li H, Hu Z, Pan P, et al. Elf5 inhibits TGF-beta-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate 2015;75:872-82
56. Xie BX, Zhang H, Wang J, Pang B, Wu RQ, Qian XL, et al. Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl 2011;32:170-82
57. Geybels MS, van Brandt PA, van Schooten FJ, Verhage BA. Oxidative stress-related genetic variants, pro-and antioxidant intake and status, and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2015;24: 178-86
58. Van Blarigan EL, Ma J, Kenfield SA, Stampfer MJ, Sesso HD, Giovannucci EL, et al. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev 2014;23:1037-46
59. Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, et al. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.HumMol Genet 2015;24:5589-602
60. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 2012;96:111-22
61. Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, E LG, Chan JM. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst 2015;107:360
62. Richman EL, Chan JM. Selenium and prostate cancer: the puzzle isn't finished yet. Am J Clin Nutr 2012;96:1-2